Clinical Trial Update: Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. [Phase 3]

View source ↗

Summary

A Phase III trial of BMS-188667 (CTLA4Ig) in rheumatoid arthritis patients who failed anti-TNF therapy has completed, with results posted in June 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• BMS-188667 (CTLA4Ig) (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2011-06-23